Tocilizumab weekly vs placebo + 52‐week taper
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in adverse events at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
- RR 1.06 [0.98, 1.16]1 study · 151 participantsModerate